Certified by Founder
Lodge
Mable | Neurolytic Healthcare
start up
United States
- San Francisco, California
- 27/07/2022
- Seed
- $3,200,000
Migraines are heritable. Uncover the link between your genetics and migraines to help prevent your migraine in advance and get medication delivered directly to your door.
- Industry Hospital & Health Care
- Website https://www.trymable.com/?utm_source=linkedin&utm_medium=social&utm_campaign=custom_button
- LinkedIn https://www.linkedin.com/company/mable-migraine-relief/
Related People
Roman RothaermelCo Founder
United Kingdom -
London, England
Before founding Mable, I was a researcher at the University of Oxford working at the intersection between neuroscience, data science and pharmacology. Today at Mable, we're using data-driven approaches to fight neurological conditions starting with migraines - a problem that affects 12% of the population and is in urgent need of innovation in care quality and delivery mechanisms.
Yuzu | $35,000,000 | (Apr 7, 2026)
Moonbounce | $12,000,000 | (Apr 7, 2026)
Insight Health AI, Inc. | $11,000,000 | (Apr 7, 2026)
Ridge AI | $2,600,000 | (Apr 7, 2026)
NeuBird AI | $19,300,000 | (Apr 7, 2026)
Stipple Bio | $100,000,000 | (Apr 7, 2026)
Noon | $44,000,000 | (Apr 7, 2026)
Miravoice | $6,300,000 | (Apr 7, 2026)
Numos | $4,250,000 | (Apr 3, 2026)
Alien | $7,100,000 | (Apr 3, 2026)
EnerVenue | $300,000,000 | (Apr 3, 2026)
Monarch Quantum | $55,000,000 | (Apr 3, 2026)